There are three reasons to be encouraged by the continued expansion of the dry eye market, according to a presenter at the OIS Dry Eye Innovation Showcase.
One is that a new product introduction may bolster the total market rather than “cannibalize” it, Donald Fishbein, MBA, president of Evolve Therapeutics, said, citing the launch of Xiidra (lifitegrast, Novartis) as an example. Fishbein noted that it is also worth watching whether market expansion will continue following the recent FDA approval of Eysuvis (loteprednol etabonate ophthalmic suspension 0.25%; Kala Pharmaceuticals).<
Uncategorized